



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Study protocol for retrospective comparative statistical assessment of automated, computer-guided Psoriasis Area and Severity Index (PASI) measurements by digital image analysis versus conventional physicians' PASI calculations

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018461
Article Type:	Protocol
Date Submitted by the Author:	30-Jun-2017
Complete List of Authors:	Fink, Christine; University Hospital Heidelberg, Department of Dermatology Uhlmann, Lorenz; University of Heidelberg, Institute of Medical Biometry and Informatics Klose, Christina; University of Heidelberg, Institute of Medical Biometry and Informatics Haenssle, Holger; University Hospital Heidelberg, Department of Dermatology
Keywords:	Psoriasis < DERMATOLOGY, PASI, Plaque Psoriasis

SCHOLARONE™
Manuscripts

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

**Study protocol for retrospective comparative statistical assessment of
automated, computer-guided PASI measurements by digital image analysis
versus conventional physicians' PASI calculations**

Authors:

Christine Fink¹, Lorenz Uhlmann², Christina Klose², Holger A Haenssle¹

Departments/Institutions:

¹Department of Dermatology, University of Heidelberg, Germany

²Institute of Medical Biometry and Informatics, University of Heidelberg, Germany

Word count: 1838

Corresponding Author:

PD Dr. med. Holger A. Haenssle

Department of Dermatology, University of Heidelberg,

Im Neuenheimer Feld 440, 69120 Heidelberg

Holger.Haenssle@med.uni-heidelberg.de

Fon: +49-6221-56-39555

Fax: +49-6221-56-4996

ABSTRACT

Introduction Reliable and accurate assessment of severity in psoriasis is very important in order to meet indication criteria for initiation of systemic treatment or to evaluate treatment efficacy. The most acknowledged tool for measuring the extent of psoriatic skin changes is the Psoriasis Area and Severity Index (PASI). However, the calculation of PASI can be tedious and subjective and high intra- and interobserver variability is an important concern. Therefore, there is a great need for a standardized and objective method that guarantees a reproducible PASI calculation.

Methods and analysis Non-interventional analyses of PASI calculations by either physicians in a prospective versus retrospective setting or an automated computer guided algorithm in 120 patients with plaque psoriasis. All retrospective PASI calculations by physicians or by the computer algorithm are based on total body digital images. The primary objective of this study is comparison of automated computer guided PASI measurements by means of digital image analysis versus conventional, prospective or retrospective physicians' PASI assessments. Secondary end points include i) the assessment of physicians' interobserver variance in PASI calculations, ii) the assessment of physicians' intraobserver variance in PASI assessments of the same patients' images after a time interval of at least 4 weeks, iii) the assessment of the deviation between physicians' prospective versus retrospective PASI calculations, iv) the reproducibility of automated computer guided PASI measurements by assessment of two sets of total body digital images of the same patients taken at one timepoint.

Ethics Ethical approval was provided by the ethic committee of the medical faculty of the University of Heidelberg. Ethics approval number S-379/2016.

Study registration This study is registered at the German Clinical Trial Register (DRKS): DRKS00011818

1

2

3

4

5

6

7 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

8

- 9
- For the first time the diagnostic performance of an automated computer guided PASI measurement will be evaluated on a large scale in daily clinical routine.
 - The primary and secondary objectives of this study address open questions of major importance for future clinical trials using PASI measurements.
 - A “golden standard” for PASI measurements is lacking. Therefore, all statistical analyses can only provide insight into differences of the level of concordance and reproducibility between PASI calculations by physicians and the computer algorithm.
 - Limitations of this study are the non-randomized and single-site setting
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29

30 **1 INTRODUCTION**

31

32

33 **1.1 Background and preliminary work**

34

35

36 Psoriasis is a chronic, inflammatory skin disease that affects 1.5% to 2 % of the population in

37 Western industrialized countries. Without adequate treatment, patients with psoriasis

38 experience a high burden of disease and a substantial restriction in quality of life [1]. Plaque

39 psoriasis is the most common clinical form of the disease and is characterized by sharply

40 demarcated erythrosquamous plaques which most frequently occur on the extensor sides of

41 the extremities [1]. Assessment of disease progress is performed by means of the Psoriasis

42 Area and Severity Index (PASI). Accurate severity scoring in psoriasis is of paramount

43 importance for determination of a medical indication for systemic therapy and the subsequent

44 surveillance of treatment efficacy. Furthermore, considerable significance is given concerning

45 the use of PASI calculations in the context of clinical trials investigating new pharmaceutical

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

drugs in psoriasis. Firstly, a certain disease severity (as measured by PASI) is a prerequisite for patient inclusion in these trials. Secondly, the assessment of the efficacy of any investigational drug in psoriasis treatment is mostly expressed by the percentage of reduction of the baseline PASI. Thus, PASI calculations represent an important measure to achieve regulatory approval for marketing of anti-psoriatic drugs. The most widely established tool and current standard for measuring the severity and extent of psoriasis is the Psoriasis Area and Severity Index (PASI) [2]. The PASI assessment is based on a complex calculation including the percentage of the body area covered by psoriatic lesions, the extent of erythema, scaling, and thickness of psoriatic plaques. For the scoring, the body is divided into the four anatomical regions head, trunk, upper and lower extremities. Both the severity of psoriatic skin lesions and the extent of the covered body surface are calculated separately. Erythema, induration, and scaling are each measured on a 0-4 visual analogue scale and the involved body surface area (BSA) is measured using a 0-6 visual analogue scale. The PASI score varies from 0 to 72. Higher scores indicate more severe disease manifestations. A 75% reduction of the baseline PASI (PASI 75) was suggested as a current benchmark for many antipsoriatic drugs under investigation in clinical trials [3]. The primary endpoint in these trials calculates the percentage of patients reaching PASI 75 after a certain time interval under treatment with the investigational drug. The PASI was developed by Fredriksson and Pettersson in 1978 as an objective means to measure the effectiveness of a retinoid during the course of the study [4]. In several subsequent studies it became apparent that the BSA measurement is the major limitation of the PASI. In most cases the involved body surface was significantly overestimated by physicians and noticeable variations between the assessors were observed. Even trained and experienced personnel showed a lack of concordance in scoring the extent of psoriasis in the same patient [5-8].

1.2 Rationale of the study

Reliable and accurate assessment of disease severity in psoriasis is of utmost importance in order to evaluate the indication for systemic treatment or treatment efficacy in daily clinical practice. Moreover, in the course of clinical trials PASI measurements are the most important indicator for patient inclusion and the evaluation of treatment efficacy of the investigational drug. To date, the most extensively studied and validated assessments tool is the PASI, which, therefore, represents the current standard. However, PASI calculations can be tedious and subjective. A major limitation of the PASI is that it is not routinely used by many clinicians and high inter- and intraobserver variability is an important concern. Several studies have shown that especially the involved body surface is often overestimated and that even experienced raters have difficulty in rating the area of involvement. In conclusion, there is a great need for a standardized and objective method for a reproducible PASI calculation.

2 DESIGN/METHODS

2.1 Study design

This is a retrospective, single-center, non-interventional study to evaluate an automated computer guided PASI measurement by digital image analysis of 120 patients suffering from plaque psoriasis in comparison to conventional PASI assessments by physicians.

2.2 Study objectives

The primary objective of this study is the comparison of automated computer guided PASI measurements by means of digital image analysis versus conventional, prospective or retrospective physicians' PASI assessments. Secondary endpoints include i) the statistical assessment of physicians' interobserver variance in PASI calculations, ii) the statistical assessment of physicians' intraobserver variance in PASI assessments of the same patients' images after a time interval of at least 4 weeks, iii) the statistical assessment of variance between physicians' prospective versus retrospective PASI calculations, iv) the

reproducibility of automated computer guided PASI measurements by assessment of two sets of total body digital images of the same patients taken at one timepoint.

2.3 Study population and criteria for inclusion/exclusion

One hundred twenty patients suffering from plaque psoriasis, undergoing medical treatment at the Department of Dermatology, University of Heidelberg and at least 18 years of age will be included in this study. Patients with other clinical types of psoriasis e.g. erythrodermic or pustular psoriasis shall be excluded from this study.

2.4 Methods

The prospective PASI calculation is performed during regular consultation and physical examination of the patient by a trained physician (*PASI 1*). Directly afterwards, total body imaging with the FotoFinder Automated Total Body Mapping (ATBM)® system will be performed. Digital images will then be used for automated computer guided measurements of PASI (*computerized PASI*) with the approved FotoFinder PASI Software for Psoriasis Quantification (PASIVision®). Automated Total Body Mapping and computerized PASI measurements will be done twice consecutively for measurement of consistency and reproducibility. Next, three other PASI-trained physicians will assess the PASI based on the analysis of the total body images (*PASI 2-4*) for measurement of inter-individual consistency. Additionally, a repeated PASI calculation of the same images at least 4 weeks after first calculation by the identical three physicians (*PASI 5-7*) will be done for measurement of intra-individual consistency (see figure 1).

FotoFinder PASI Software for Psoriasis Quantification (PASIVision®) is an approved medical class I device. The software automatically calculates the PASI based on 16 polarized digital images covering the whole body surface made with the FotoFinder Automated Total Body Mapping (ATBM)® system. ATBM® enables standardized documentation of the entire skin

surface, except hairy scalp and genital area. The calculation and presentation of the computerized PASI score complies with the validated method of standardized PASI scoring [9]. Study data will be collected and managed by the Institute of Medical Biometry and Informatics (IMBI) at the University of Heidelberg using the Research Electronic Data Capture (REDCap) tool. REDCap is a secure, web-based application designed to support data capture for research studies providing an intuitive interface for validated data entry, audit trails for tracking data manipulation and export procedures, automated export procedures for seamless data downloads to common statistical packages and procedures for importing data from external sources [10]. The individual values of the PASI will be directly entered in the REDCap database by the physicians during evaluation of the total body images. After PASI data for all patients has been entered by the three physicians (*PASI 2-4*) the database will be locked for 4 weeks and PASI assessments can then be repeated (*PASI 5-7*) at the earliest availability of the three physicians. The time interval of at least 4 weeks between the two assessments is sufficiently long to exclude that physicians remember earlier PASI scorings of the 120 patients. Physician will have neither access to their previously entered data nor to PASI scores of other physicians.

2.5 Statistical considerations

2.5.1 Sample size calculation

This is a retrospective non-interventional analysis of digital images of 120 patients with plaque psoriasis. Only descriptive statistics will be applied. The general objective of this study is not proving superiority of one method over the other, but to evaluate concordance and reproducibility of PASI calculations. Due to feasibility reasons, a sample size of 120 fully

evaluable patient datasets will be collected. This sample size is sufficient to assess the performance of the computer algorithm as well as inter- and intra-observer variability [11].

2.5.2 Statistical analysis

All PASI score results will be analyzed descriptively by tabulation of the mean and standard deviation, medians, and first and third quartiles, as well as minimum and maximum. The intra-class correlation coefficient measuring the agreement between computerized PASI versus physicians' PASI, the reproducibility of computerized PASI, and the inter-rater as well as intra-rater reliability will be calculated. Bland-Altman plots will be created to visualize the agreement of the values. Mean bias and limits of agreement will be calculated.

2.6 Ethical considerations and regulatory obligations

The information contained in this protocol and the implementation of the study is consistent with the moral, ethical, and scientific principles governing clinical research as set out in the Declaration of Helsinki (2013), the principles of ICH-GCP guidelines (E6) and the current laws. This study is performed in the context of the approved standard operating procedures (SOPs) which are based on ICH-GCP guidelines (E6) and the German implementation of Good clinical practice (GCP) for clinical work. Before initiation of the study, the protocol was presented to the independent ethics committee of the medical faculty of the University of Heidelberg. Ethics approval was granted by the ethics committee in September 2016 (Ethics approval number S-379/2016). All included patients shall provide written informed consent which is required for the acquisition and further processing of digital total body images. This study falls within the legal category of „in-house research” according to the German „Landesdatenschutzgesetz” §15 section 3 (Rechtsgrundlagen der Datenverarbeitung). All digital images processed in this study were collected within the framework of routine medical care according to the standard operating procedures (SOP) of the Department of Dermatology

at the University of Heidelberg and current treatment guidelines. This implies that the presented study does not require any direct patient related procedures. The names of patients and all confidential data are subject to professional discretion and the “Bundesdatenschutzgesetz (BDSG)”. Processing of medical data will only take place in pseudonymous form. Third persons will not be allowed access to patient data. There is no personal benefit and no additional risks for study participants.

3 FOOTNOTES

3.1 Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

3.2 Study registration

This study is registered at the German Clinical Trial Register (DRKS): DRKS00011818 (<https://www.germanctr.de/>).

3.3 Conflicts of interest

The authors declared that they have no competing interests.

3.4.1 Authors’ contribution

C. Fink, C. Klose, L. Uhlmann and H.A. Haenssle participated in the development and the implementation of the study (writing of the protocol, submission to ethics committee, data management). Fink, C. Klose, L. Uhlmann and H.A. Haenssle helped to draft and to review the paper. All authors read and approved the final manuscript.

4 REFERENCES

1. Nast A, Boehncke WH, Mrowietz et al. S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2012;10: S1–s95.
2. Bronsard V, Paul C, Prey S et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. Journal of the European Academy of Dermatology and Venereology. (2010) 24: 17–22. doi:10.1111/j.1468-3083.2009.03563.x
3. Carlin CS, Feldman SR, Krueger JG et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004 Jun;50(6):859-66.
4. Fredriksson T, Pettersson U (1978): Severe Psoriasis – Oral Therapy with a New Retinoid. Dermatologica 157: 238–244
5. Ramsay B, Lawrence C M (1991): Measurement of involved surface area in patients with psoriasis. British Journal of Dermatology 124: 565–570
6. Bahmer F (1989): The Size of Lesions, or Point Counting as a step toward the Solution of the PASI Problem. Arch Dermatol 125: 1282-1283
7. Marks R, Barton S P, Shuttleworth D, Finlay A Y (1989): Assessment of Disease Progress in Psoriasis. Arch Dermatol 125: 235–240
8. Faust H B, Gonin R, Chuang T Y, Lewis C W, Melfi C A, Farmer E R (1997): Reliability Testing of the Dermatology Index of Disease Severity (DIDS). Arch Dermatol 133: 1443-1448]
9. FotoFinder PASIvision. <https://www.fotofinder.de/produkte/pasivision/> (Data retrieved on 07/2017)
10. Paul A. Harris, Robert Taylor, Robert Thielke, Jonathon Payne, Nathaniel Gonzalez, Jose G. Conde, Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform. 2009 Apr;42(2):377-81.

11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–310.

5 **FIGURES**

Figure 1

Flowchart of the study

For peer review only




Figure 1
Flowchart of the study

177x99mm (300 x 300 DPI)

BMJ Open

Automated, computer-guided PASI measurements by digital image analysis versus conventional physicians' PASI calculations: study protocol for a comparative, single-center, observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018461.R1
Article Type:	Protocol
Date Submitted by the Author:	12-Feb-2018
Complete List of Authors:	Fink, Christine; University Hospital Heidelberg, Department of Dermatology Uhlmann, Lorenz; University of Heidelberg, Institute of Medical Biometry and Informatics Klose, Christina; University of Heidelberg, Institute of Medical Biometry and Informatics Haenssle, Holger; University Hospital Heidelberg, Department of Dermatology
Primary Subject Heading:	Dermatology
Secondary Subject Heading:	Dermatology, Diagnostics
Keywords:	Psoriasis < DERMATOLOGY, PASI, Plaque Psoriasis

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Automated, computer-guided PASI measurements by digital image analysis *versus* conventional physicians' PASI calculations: study protocol for a comparative, single-center, observational study

Authors:

Christine Fink¹, Lorenz Uhlmann², Christina Klose², Holger A Haenssle¹

Departments/Institutions:

¹Department of Dermatology, University of Heidelberg, Germany

²Institute of Medical Biometry and Informatics, University of Heidelberg, Germany

Word count: 1838

Corresponding Author:

Prof. Dr. med. Holger A. Haenssle

Department of Dermatology, University of Heidelberg,

Im Neuenheimer Feld 440, 69120 Heidelberg

Holger.Haenssle@med.uni-heidelberg.de

Fon: +49-6221-56-39555

Fax: +49-6221-56-4996

ABSTRACT

Introduction Reliable and accurate assessment of severity in psoriasis is very important in order to meet indication criteria for initiation of systemic treatment or to evaluate treatment efficacy. The most acknowledged tool for measuring the extent of psoriatic skin changes is the Psoriasis Area and Severity Index (PASI). However, the calculation of PASI can be tedious and subjective and high intra- and inter-observer variability is an important concern. Therefore, there is a great need for a standardized and objective method that guarantees a reproducible PASI calculation. Within this study we will investigate the precision and reproducibility of automated, computer-guided PASI measurements in comparison to trained physicians to address these limitations.

Methods and analysis Non-interventional analyses of PASI calculations by either physicians in a prospective versus retrospective setting or an automated computer guided algorithm in 120 patients with plaque psoriasis. All retrospective PASI calculations by physicians or by the computer algorithm are based on total body digital images. The primary objective of this study is comparison of automated computer guided PASI measurements by means of digital image analysis versus conventional, prospective or retrospective physicians' PASI assessments. Secondary end points include i) the assessment of physicians' inter-observer variance in PASI calculations, ii) the assessment of physicians' intra-observer variance in PASI assessments of the same patients' images after a time interval of at least 4 weeks, iii) the assessment of the deviation between physicians' prospective versus retrospective PASI calculations, iv) the reproducibility of automated computer guided PASI measurements by assessment of two sets of total body digital images of the same patients taken at one time point.

Ethics Ethical approval was provided by the ethic committee of the medical faculty of the University of Heidelberg. Ethics approval number S-379/2016.

Study registration This study is registered at the German Clinical Trial Register (DRKS):
DRKS00011818

STRENGTHS AND LIMITATIONS OF THIS STUDY

- For the first time the diagnostic performance of an automated computer guided PASI measurement will be evaluated on a large scale in daily clinical routine.
- The primary and secondary objectives of this study address open questions of major importance for future clinical trials using PASI measurements.
- A “golden standard” for PASI measurements is lacking. Therefore, all statistical analyses can only provide insight into differences of the level of concordance and reproducibility between PASI calculations by physicians and the computer algorithm.
- Limitations of this study are the non-randomized and single-site setting

1 INTRODUCTION

1.1 Background and preliminary work

Psoriasis is a chronic, inflammatory skin disease that affects 1.5% to 2 % of the population in Western industrialized countries. Without adequate treatment, patients with psoriasis experience a high burden of disease and a substantial restriction in quality of life [1]. Plaque psoriasis is the most common clinical form of the disease and is characterized by sharply demarcated erythrosquamous plaques which most frequently occur on the extensor sides of the extremities [1]. Assessment of disease progress is performed by means of the Psoriasis Area and Severity Index (PASI). Accurate severity scoring in psoriasis is of paramount importance for determination of a medical indication for systemic therapy and the subsequent

surveillance of treatment efficacy. Furthermore, considerable significance is given concerning the use of PASI calculations in the context of clinical trials investigating new pharmaceutical drugs in psoriasis. Firstly, a certain disease severity (as measured by PASI) is a prerequisite for patient inclusion in these trials. Secondly, the assessment of the efficacy of any investigational drug in psoriasis treatment is mostly expressed by the percentage of reduction of the baseline PASI. Thus, PASI calculations represent an important measure to achieve regulatory approval for marketing of anti-psoriatic drugs. The PASI assessment is based on a complex calculation including the percentage of the body area covered by psoriatic lesions, the extent of erythema, scaling, and thickness of psoriatic plaques. For the scoring, the body is divided into the four anatomical regions head, trunk, upper and lower extremities. Both the severity of psoriatic skin lesions and the extent of the covered body surface are calculated separately. Erythema, induration, and scaling are each measured on a 0-4 visual analogue scale and the involved body surface area (BSA) is measured using a 0-6 visual analogue scale [1]. The PASI score varies from 0 to 72. Higher scores indicate more severe disease manifestations [1]. A 75% reduction of the baseline PASI (PASI 75) was suggested as a current benchmark for many antipsoriatic drugs under investigation in clinical trials [2]. The primary endpoint in these trials calculates the percentage of patients reaching PASI 75 after a certain time interval under treatment with the investigational drug. The PASI was developed by Fredriksson and Pettersson in 1978 as an objective means to measure the effectiveness of a retinoid during the course of the study [3]. In several subsequent studies it became apparent that the BSA measurement is one of the major limitations of the PASI. Besides the 'rule of nine' the BSA calculation was often based on the 'one hand method' since it was assumed that the area of a flat patients' hand represents 1% of his total BSA [4]. In most cases the involved body surface was significantly overestimated by physicians and noticeable variations between the assessors were observed. Even trained and experienced personnel showed a lack of concordance in scoring the extent of psoriasis in the same patient [5-8]. Meanwhile, it has

been shown that one hand actually represents 0.70-0.76% of the BSA which might be one possible explanation for surface overestimation [9]. Additionally, time pressure during the consultation is undoubtedly another important influence on the high intra- and inter-observer variability. Of note, PASI is not taking relevant patient reported outcomes such as pain and itch into account. Therefore, several alternative scores for psoriasis severity assessment were implemented more recently [10]. For example an innovative and alternative severity score based on the dermoscopic vascular pattern of psoriatic skin lesions was suggested by Carlesimo et al. [11]. Finally, a further limitation of the PASI is that it is not routinely used by many clinicians. However, PASI allows for historical comparisons between clinical trials evaluating different anti-psoriatic drugs and will therefore still be widely applied.

1.2 Rationale of the study

A reproducible, standardized and objective assessment of disease severity in psoriasis is of utmost importance in order to evaluate the indication for systemic treatment or treatment efficacy in daily clinical practice. To date, the most extensively studied and validated assessments tool is the PASI, which, therefore, represents the current standard. However, significant concerns arise from PASI’s inherent level of subjectivity and high inter- and intra-observer variability. Therefore, within this study we will investigate the precision and reproducibility of automated, computer-guided PASI measurements in comparison to trained physicians.

2 DESIGN/METHODS

2.1 Study design

This is a retrospective, single-center, non-interventional study to evaluate an automated computer guided PASI measurement by digital image analysis of 120 patients suffering from plaque psoriasis in comparison to conventional PASI assessments by physicians.

2.2 Study objectives

The primary objective of this study is to investigate the precision of automated computer guided PASI measurements by means of digital image analysis versus conventional, prospective or retrospective physicians' PASI assessments. Secondary endpoints include i) the statistical assessment of physicians' inter-observer variance in PASI calculations, ii) the statistical assessment of physicians' intra-observer variance in PASI assessments of the same patients' images after a time interval of at least 4 weeks, iii) the statistical assessment of variance between physicians' prospective versus retrospective PASI calculations, iv) the reproducibility of automated computer guided PASI measurements by assessment of two sets of total body digital images of the same patients taken at one time point.

2.3 Study population and criteria for inclusion/exclusion

One hundred twenty patients suffering from plaque psoriasis, undergoing medical treatment at the Department of Dermatology, University of Heidelberg and at least 18 years of age will be included in this study. Patients with other clinical types of psoriasis e.g. erythrodermic or pustular psoriasis shall be excluded from this study.

2.4 Methods

The prospective PASI calculation will be performed during regular consultation and physical examination of the patient by a trained physician (*pPASI I*). Directly afterwards, total body imaging with the FotoFinder Automated Total Body Mapping (ATBM)® system will be performed (ATBI 1+2). Digital images will then be used for automated computer guided

measurements (ACPM) of PASI (*computerized cPASI 1+2*) with the approved FotoFinder PASI Software for Psoriasis Quantification (PASIVision®). Automated Total Body Mapping and computerized PASI measurements will be done twice consecutively for measurement of consistency and reproducibility. Next, three other PASI-trained physicians (*P2-4*) will assess the PASI based on the analysis of the total body images (*rPASI 1-3*) for measurement of inter-individual consistency. Additionally, a repeated PASI calculation of the same images at least 4 weeks after first calculation by the identical three physicians (*rPASI 4-6*) will be done for measurement of intra-individual consistency (see figure 1). Physicians were considered experienced PASI raters if they had been formally trained and had been involved in at least 20 clinical psoriasis trials over the last three years. FotoFinder PASI Software for Psoriasis Quantification (PASIVision®) is an approved medical class I device. The software automatically calculates the PASI based on 16 polarized digital images covering the whole body surface made with the FotoFinder Automated Total Body Mapping (ATBM®) system. ATBM® enables standardized documentation of the entire skin surface, except hairy scalp and genital area. Of note, for this study we will use the computerized PASI scores without any further adjustments. However, the software offers physicians the opportunity to customize and adjust the computerized PASI in a final step before storage. The calculation and presentation of the computerized PASI score complies with the validated method of standardized PASI scoring [12]. Study data will be collected and managed by the Institute of Medical Biometry and Informatics (IMBI) at the University of Heidelberg using the Research Electronic Data Capture (REDCap) tool. REDCap is a secure, web-based application designed to support data capture for research studies providing an intuitive interface for validated data entry, audit trails for tracking data manipulation and export procedures, automated export procedures for seamless data downloads to common statistical packages and procedures for importing data from external sources [13]. The individual values of the PASI will be directly entered in the REDCap database by the physicians during evaluation of the total body images. After PASI

data for all patients has been entered by the three physicians (*rPASI 1-3*) the database will be locked for 4 weeks and PASI assessments can then be repeated (*rPASI 4-6*) at the earliest availability of the three physicians. The time interval of at least 4 weeks between the two assessments is sufficiently long to exclude that physicians remember earlier PASI scorings of the 120 patients. Physician will have neither access to their previously entered data nor to PASI scores of other physicians or to the computerized PASI scores.

2.5 Statistical considerations

2.5.1 Sample size calculation

This is a retrospective non-interventional analysis of digital images of 120 patients with plaque psoriasis. Only descriptive statistics will be applied. The general objective of this study is not proving superiority of one method over the other, but to evaluate concordance and reproducibility of PASI calculations. Due to feasibility reasons, a sample size of 120 fully evaluable patient datasets will be collected. This sample size is sufficient to assess the performance of the computer algorithm as well as inter- and intra-observer variability [14].

2.5.2 Statistical analysis

All PASI score results will be analyzed descriptively by tabulation of the mean and standard deviation. The Intraclass-Correlation-Coefficient (ICC) will be used to measure the agreement between computerized and physicians' PASI, the reproducibility of computerized PASI and the inter-rater and intra-rater reliability. Bland-Altman plots will be used to visualize the agreements. Mean bias between the PASI measurements and limits of agreement will be calculated. The analyses will be carried out using R (V3.3.1) with the packages car (V2.1-5), multilevel (V2.6), MASS (V7.3-45), nlme (V3.1-128), xtable (V1.8-2) and psychometric (V2.2) [15].

2.6 Ethical considerations, dissemination plan, and regulatory obligations

The information contained in this protocol and the implementation of the study is consistent with the moral, ethical, and scientific principles governing clinical research as set out in the Declaration of Helsinki (2013), the principles of ICH-GCP guidelines (E6) and the current laws. This study will be performed in the context of the approved standard operating procedures (SOPs) which are based on ICH-GCP guidelines (E6) and the German implementation of Good clinical practice (GCP) for clinical work. Before initiation of the study, the protocol was presented to the independent ethics committee of the medical faculty of the University of Heidelberg. Ethics approval was granted by the ethics committee in September 2016 (Ethics approval number S-379/2016). All included patients shall provide written informed consent which is required for the acquisition and further processing of digital total body images. This study falls within the legal category of „in-house research” according to the German „Landesdatenschutzgesetz” §15 section 3 (Rechtsgrundlagen der Datenverarbeitung). All digital images processed in this study were collected within the framework of routine medical care according to the standard operating procedures (SOP) of the Department of Dermatology at the University of Heidelberg and current treatment guidelines. This implies that the presented study does not require any direct patient related procedures. The names of patients and all confidential data are subject to professional discretion and the German Federal Data Protection Act (Bundesdatenschutzgesetz (BDSG)). Processing of medical data will only take place in pseudonymous form. Third persons will not be allowed access to patient data. There is no personal benefit and no additional risks for study participants. The design and the final results of the study will be published and made available to the public in the form of congress presentations, press releases, and manuscripts

submitted to scientific journals. Data storage is in accordance with the German Federal Data Protection Act (BDSG). Study records will be kept for 10 years.

3 FOOTNOTES

3.1 Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

3.2 Study registration

This study is registered at the German Clinical Trial Register (DRKS): DRKS00011818 (<https://www.germanctr.de/>).

3.3 Conflicts of interest

The authors declared that they have no competing interests.

3.4.1 Authors' contribution

C. Fink, C. Klose, L. Uhlmann and H.A. Haenssle participated in the development and the implementation of the study (writing of the protocol, submission to ethics committee, data management). Fink, C. Klose, L. Uhlmann and H.A. Haenssle helped to draft and to review the paper. All authors read and approved the final manuscript.

4 REFERENCES

1. Nast A, Boehncke WH, Mrowietz et al. S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2012;10: S1–s95.

2. Carlin CS, Feldman SR, Krueger JG et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004 Jun;50(6):859-66.

3. Fredriksson T, Pettersson U (1978): Severe Psoriasis – Oral Therapy with a New Retinoid. Dermatologica 157: 238–244

4. Puzenat E, Bronsard V, Prey S et al. (2010), What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. Journal of the European Academy of Dermatology and Venereology, 24: 10–16. doi:10.1111/j.1468-3083.2009.03562.x

5. Ramsay B, Lawrence C M (1991): Measurement of involved surface area in patients with psoriasis. British Journal of Dermatology 124: 565–570

6. Bahmer F (1989): The Size of Lesions, or Point Counting as a step toward the Solution of the PASI Problem. Arch Dermatol 125: 1282-1283

7. Marks R, Barton S P, Shuttleworth D, Finlay A Y (1989): Assessment of Disease Progress in Psoriasis. Arch Dermatol 125: 235–240

8. Faust H B, Gonin R, Chuang T Y, Lewis C W, Melfi C A, Farmer E R (1997): Reliability Testing of the Dermatology Index of Disease Severity (DIDS). Arch Dermatol 133: 1443-1448]

9. Long CC, Finlay AY, Averill RW. The Rule of Hand: 4 Hand Areas=2 FTU=1 g. Arch Dermatol. 1992;128(8):1129–1130. doi:10.1001/archderm.1992.01680180125022

BMJ Open: first published as 10.1136/bmjopen-2017-018461 on 17 May 2018. Downloaded from <http://bmjopen.bmj.com/> on June 14, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

10. Gottlieb A, Feng J, Harrison DJ, Globe D. Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. *J Am Acad Dermatol*. 2010 Oct;63(4):580-6. doi: 10.1016/j.jaad.2009.09.049.
11. Carlesimo M, Garelli V, Fortuna MC et al. Vascular Psoriasis Area Severity Index: A dermoscopic standard technique for assessing severity psoriasis and therapeutic management. *J Dermatol Sci*. 2017 Jun;86(3):249-251. doi: 10.1016/j.jdermsci.2017.03.010. Epub 2017 Mar 21.
12. FotoFinder PASIvision. <https://www.fotofinder.de/produkte/pasivision/> (Data retrieved on 07/2017)
13. Paul A. Harris, Robert Taylor, Robert Thielke, Jonathon Payne, Nathaniel Gonzalez, Jose G. Conde, Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support, *J Biomed Inform*. 2009 Apr;42(2):377-81.
14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986;1:307–310.
15. R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.

5 FIGURES


Figure 1

Flowchart of the study. At the first consultation each patient will be examined by a PASI trained physician (P1) who will prospectively attain pPASI 1. Each patient will then be send for automated total body imaging (ATBI) and calculation of the computerized PASI (cPASI 1+2) by automated computer-guided PASI measurements (ACPM). ATBI and ACPM will be done twice consecutively for measurement of consistency and reproducibility. The digital pictures of the total body imaging will

then be used for PASI calculation by three further trained physicians (P2-P4) resulting in rPASI 1-3.

After at least 4 weeks the same three physicians will perform a second assessment of the total body images and calculate rPASI 4-6.

For peer review only



103x158mm (300 x 300 DPI)